YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Xia, Yong ^a   Song, Xuejiao ^a   Li, Deliang ^a   Ye, Tinghong ^a   Xu, Youzhi ^b   Lin, Hongjun ^a   Meng, Nana ^a   Li, Guobo ^a   Deng, Senyi ^a   Zhang, Shuang ^a   Liu, Li ^a   Zhu, Yongxia ^a   Zeng, Jun ^a   Lei, Qian ^a   Pan, Youli ^a   Wei, Yuquan ^a   Zhao, Yinglan ^a   Yu, Luoting ^a  

^a SICHUAN UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PICOLINIC ACID DERIVATIVE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; YLT192;

ANGIOGENESIS; ANIMAL; ANIMAL EMBRYO; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BINDING SITE; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; FEMALE; GROWTH, DEVELOPMENT AND AGING; HCT116 CELL LINE; HUMAN; MALE; METABOLISM; MOUSE; NEOPLASMS; NUDE MOUSE; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; RAT; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; WISTAR RAT; ZEBRA FISH;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BINDING SITES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EMBRYO, NONMAMMALIAN; FEMALE; HCT116 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; PICOLINIC ACIDS; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; ZEBRAFISH;

EID: 84921366701     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06031     Document Type: Article

References (50)

1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
2. Cho, S. G. et al. Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. Cancer Res. 69, 7062-7070, doi:10.1158/0008-5472.can-09-0476 (2009).
3. Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2, 795-803, doi:10.1038/nrc909 (2002).
4. Ivy, S. P., Wick, J. Y. & Kaufman, B. M. An overview of small-molecule inhibitors of VEGFR signaling. Nat. Rev. Clin. Oncol. 6, 569-579, doi:10.1038/nrclinonc.2009.130 (2009).
5. Wiesmann, C. et al. Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91, 695-704 (1997).
6. Lu, D. et al. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies. J. Biol.Chem. 275, 14321-14330 (2000).
7. van der Meel, R. et al. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. Drug Discov. Today 16, 219-228 (2011).
8. Rak, J. et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55, 4575-4580 (1995).
9. Mukhopadhyay, D., Knebelmann, B., Cohen, H. T., Ananth, S. & Sukhatme, V. P. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol. 17, 5629-5639 (1997).
10. Zhou, Y.-J. et al. Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer. World J. Gastroenterol. 10, 3225-3229 (2004).
11. Shweiki, D., Neeman, M., Itin, A. & Keshet, E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc. Natl. Acad. Sci. U S A 92, 768-772 (1995).
12. Wedge, S. R. et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389-4400 (2005).
13. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
14. Mendel, D. B. et al. In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors Determination of a Pharmacokinetic/Pharmacodynamic Relationship. Clin. Cancer Res. 9, 327-337 (2003).
15. Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109, doi:10.1158/0008-5472.CAN-04-1443 (2004).
16. Morabito, A. et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 14, 378-390, doi:10.1634/theoncologist.2008-0261 (2009).
17. Wang, Z. et al. Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PloS one 8, e68566 (2013).
18. Yang, H.-Y. et al. Anti-Cancer Activity of an Osthole Derivative, NBM-T-BMX-OS01: Targeting Vascular Endothelial Growth Factor Receptor Signaling and Angiogenesis. PloS one 8, e81592 (2013).
19. Elice, F. & Rodeghiero, F. Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thrombosis Res. 125, S55-S57 (2010).
20. Shibuya, M. Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 13, 63-69 (2006).
21. Nikitenko, L. & Boshoff, C. in The Vascular Endothelium II 307-334 (Springer, 2006).
22. Molina, D. M. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87 (2013).
23. Huang, S. & Houghton, P. J. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 3, 371-377 (2003).
24. Cao, Z. X. et al. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. Cell Physiol. Biochem. 27, 565-574, doi:10.1159/000329978 (2011).
25. Wu, L.-W. et al. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J. Biol. Chem. 275, 5096-5103 (2000).
26. Shiojima, I. & Walsh, K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circulation Res. 90, 1243-1250 (2002).
27. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732 (2003).
28. Gordan, J. D. & Simon, M. C. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr. Opin. Genet. Dev. 17, 71-77 (2007).
29. Jung, J. E. et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J. 19, 1296-1298 (2005).
30. Auerbach, R., Lewis, R., Shinners, B., Kubai, L. & Akhtar, N. Angiogenesis assays: a critical overview. Clin. Chem. 49, 32-40 (2003).
31. Tran, T. C. et al. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res. 67, 11386-11392 (2007).
32. Zhang, S. et al. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin. Cancer Res. 17, 4439-4450, doi:10.1158/1078-0432.CCR-10-3109 (2011).
33. Yang, F. et al. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol. Cancer Ther. 9, 953-962, doi:10.1158/1535-7163.MCT-09-0947 (2010).
34. Santarpia, L., Lippman, S. M. & El-Naggar, A. K. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin. Ther. Targets 16, 103-119 (2012).
35. Zhang, Z., Zhou, X., Shen, H., Wang, D. & Wang, Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 7, 41 (2009).
36. Jing, N. & Tweardy, D. J. Targeting Stat3 in cancer therapy. Anti-cancer drugs 16, 601-607 (2005).
37. Yu, H. & Jove, R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4, 97-105, doi:10.1038/nrc1275 (2004).
38. Pathak, A. K. et al. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol. Cancer Ther. 5, 943-955 (2007).
39. Chen, J. et al. Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer. Mol. Cancer Ther. 11, 277-287 (2012).
40. Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619 (2006).
41. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554-554 (2004).
42. Markman, B., Dienstmann, R. & Tabernero, J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 1, 530 (2010).
43. Pang, X. et al. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 70, 1951-1959 (2010).
44. Chehrehasa, F., Meedeniya, A. C., Dwyer, P., Abrahamsen, G. & Mackay-Sim, A. EdU, a new thymidine analogue for labelling proliferating cells in the nervous system. J. Neurosci. Methods 177, 122-130 (2009).
45. Ye, T. et al. The Anthelmintic Drug Niclosamide Induces Apoptosis, Impairs Metastasis and Reduces Immunosuppressive Cells in Breast Cancer Model. PloS one 9, e85887 (2014).
46. Wu, H.-T., Lin, S.-H. & Chen, Y.-H. Inhibition of cell proliferation and in vitro markers of angiogenesis by indole-3-carbinol, a major indole metabolite present in cruciferous vegetables. J. Agric. Food Chem. 53, 5164-5169 (2005).
47. Hoffmann, J., Schirner, M., Menrad, A. & Schneider, M. R. A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res. 57, 3847-3851 (1997).
48. Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. & Schilling, T. F. Stages of embryonic development of the zebrafish. Dev. Dynam. 203, 253-310 (1995).
49. Blezinger, P. et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat. Biotechnol. 17, 343-348 (1999).
50. Wedge, S. R. et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62, 4645-4655 (2002).